Literature DB >> 11966752

Does normalization of prolactin levels result in weight loss in patients with prolactin secreting pituitary adenomas?

R Yermus1, S Ezzat.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11966752     DOI： 10.1046/j.1365-2265.2002.01510.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN： 0300-0664            Impact factor:   3.478


× No keyword cloud information.
  7 in total

1.  The effect of the ANKK1/DRD2 Taq1A polymorphism on weight changes of dopaminergic treatment in prolactinomas.

Authors:  A P Athanasoulia; C Sievers; M Uhr; M Ising; G K Stalla; H J Schneider
Journal:  Pituitary       Date:  2014-06       Impact factor: 4.107

Review 2.  Diagnosis and management of hyperprolactinemia.

Authors:  Omar Serri; Constance L Chik; Ehud Ur; Shereen Ezzat
Journal:  CMAJ       Date:  2003-09-16       Impact factor: 8.262

3.  Evaluation of body weight, insulin resistance, leptin and adiponectin levels in premenopausal women with hyperprolactinemia.

Authors:  Aysegul Atmaca; Birsen Bilgici; Gulcin Cengiz Ecemis; Ozgur Korhan Tuncel
Journal:  Endocrine       Date:  2013-03-26       Impact factor: 3.633

Review 4.  The effects of hyperprolactinemia on bone and fat.

Authors:  Amal Shibli-Rahhal; Janet Schlechte
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

5.  10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.

Authors:  Lukas Andereggen; Janine Frey; Robert H Andres; Marwan El-Koussy; Jürgen Beck; Rolf W Seiler; Emanuel Christ
Journal:  Endocrine       Date:  2016-09-29       Impact factor: 3.633

6.  Profile of leptin, adiponectin, and body fat in patients with hyperprolactinemia: Response to treatment with cabergoline.

Authors:  Nazir Ahmad Pala; Bashir Ahmad Laway; Raiz Ahmad Misgar; Zaffar Amin Shah; Tariq A Gojwari; Tariq A Dar
Journal:  Indian J Endocrinol Metab       Date:  2016 Mar-Apr

Review 7.  Neuropsychiatric and metabolic aspects of dopaminergic therapy: perspectives from an endocrinologist and a psychiatrist.

Authors:  Anastasia P Athanasoulia-Kaspar; Kathrin H Popp; Gunter Karl Stalla
Journal:  Endocr Connect       Date:  2018-01-29       Impact factor: 3.335
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.